Updated Phase 1 Data Support Further Research of Botensilimab/Balstilimab in Refractory MSS CRC

Updated phase 1 findings with botensilimab/balstilimab in MSS/pMMR mCRC show that the regimen elicited respective 12- and 18-month OS rates of 71% and 62%.

Related Keywords

United States , ,Agenus Inc ,Botensilimab ,Balstilimab ,Dmcrc ,Colorectal Cancer ,